title: Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm.
abstract: In the setting of catheter-related bloodstream infections, intraluminal antibiotic lock therapy could be useful for the salvage of vascular catheters. In this in vitro study, we investigated the efficacies of the newer antibiotics daptomycin, linezolid, and tigecycline, in comparison with those of vancomycin, minocycline, and rifampin, against methicillin-resistant Staphylococcus aureus (MRSA) embedded in biofilm. We also assessed the emergence of MRSA strains resistant to these antibiotics, alone or in combination with rifampin, after 4-hour daily use for catheter lock therapy. Minocycline, daptomycin, and tigecycline were more efficacious in inhibiting MRSA in biofilm than linezolid, vancomycin, and the negative control (P < 0.001) after the first day of exposure to these antibiotics, with minocycline being the most active, followed by daptomycin and then tigecycline, and with vancomycin and linezolid lacking activity, similar to the negative control. After 3 days of 4-hour daily exposures, daptomycin was the fastest in eradicating MRSA from biofilm, followed by minocycline and tigecycline, which were faster than linezolid, rifampin, and vancomycin (P < 0.001). When rifampin was used alone, it was the least effective in eradicating MRSA from biofilm after 5 days of 4-hour daily exposures, as it was associated with the emergence of rifampin-resistant MRSA. However, when rifampin was used in combination with other antibiotics, the combination was significantly effective in eliminating MRSA colonization in biofilm more rapidly than each of the antibiotics alone. In summary, daptomycin, minocycline, and tigecycline should be considered further for antibiotic lock therapy, and rifampin should be considered for enhanced antistaphylococcal activity but not as a single agent.
authors.affiliation: The University of Texas M D Anderson Cancer Center, Department of Infectious Diseases, Infection Control and Employee Health, Houston, TX 77030, USA.
authors.forename: Issam
authors.initials: I
authors.lastname: Raad
authors.forename: Hend
authors.initials: H
authors.lastname: Hanna
authors.forename: Ying
authors.initials: Y
authors.lastname: Jiang
authors.forename: Tanya
authors.initials: T
authors.lastname: Dvorak
authors.forename: Ruth
authors.initials: R
authors.lastname: Reitzel
authors.forename: Gassan
authors.initials: G
authors.lastname: Chaiban
authors.forename: Robert
authors.initials: R
authors.lastname: Sherertz
authors.forename: Ray
authors.initials: R
authors.lastname: Hachem
mesh_terms: D000081:Acetamides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016470:Bacteremia / Q000382:microbiology*; D018441:Biofilms; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D017576:Daptomycin / Q000494:pharmacology*; D006801:Humans; D000069349:Linezolid; D016106:Methicillin Resistance; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D023303:Oxazolidinones / Q000494:pharmacology*; D013211:Staphylococcus aureus / Q000187:drug effects*; D000078304:Tigecycline
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D000078304:Tigecycline; D008911:Minocycline; D000069349:Linezolid; D017576:Daptomycin